Get started
Author

Kun‐Ming Rau

Observed names: KUN-MING RAU, Kun-Ming Rau, Rau, Kun-Ming
ORCID: 0000-0002-1209-3043
Observed ORCID: 0000-0002-1209-3043
OpenAlex ID: A5112485163
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · Andrew X Zhu, Yoon-Koo Kang, et al. · The Lancet Oncology · 1,724
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
2015 · Andrea Wang-Gillam, Chung-Pin Li, et al. · The Lancet · 1,278
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · Shukui Qin, Stephen L Chan, et al. · The Lancet · 798
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 237
PDF
Resveratrol Modulates Tumor Cell Proliferation and Protein Translation via SIRT1-Dependent AMPK Activation
2009 · Jia-Ni Lin, Victor Chia-Hsiang Lin, et al. · Journal of Agricultural and Food Chemistry · 142
Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients
2005 · Shau-Hsuan Li, Wei-Hsi Chen, et al. · Clinical Neurology and Neurosurgery · 116
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
2018 · Andrew X. Zhu, Yoon-Koo Kang, et al. · Journal of Clinical Oncology · 103
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
2014 · Ho Yeong Lim, Jeong Heo, et al. · Clinical Cancer Research · 99
PDF
Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
2015 · Yen-Shen Lu, Tom Wei-Wu Chen, et al. · Clinical Cancer Research · 79
Comparative Study of Esophageal Stent and Feeding Gastrostomy/Jejunostomy for Tracheoesophageal Fistula Caused by Esophageal Squamous Cell Carcinoma
2012 · Yen-Hao Chen, Shau-Hsuan Li, et al. · PLoS ONE · 78
PDF
Albumin‐Bilirubin grade predicts prognosis of HCC patients with sorafenib use
2017 · Yuan‐Hung Kuo, Jing‐Houng Wang, et al. · Journal of Gastroenterology and Hepatology · 68
A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer
2016 · Ming-Yen Tsai, Yu-Chiang Hung, et al. · BMC Complementary and Alternative Medicine · 49
PDF
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
2019 · Yung‐Jue Bang, Chung‐Pin Li, et al. · Cancer Science · 48
PDF
Chromogranin A Is a Reliable Biomarker for Gastroenteropancreatic Neuroendocrine Tumors in an Asian Population of Patients
2012 · Wen-Chi Chou, Yu-Shin Hung, et al. · Neuroendocrinology · 45
Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma C a S ki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways
2013 · Tai‐Long Pan, Pei‐Wen Wang, et al. · PROTEOMICS · 44
TMPRSS6 rs855791 Polymorphism Influences the Susceptibility to Iron Deficiency Anemia in Women at Reproductive Age
2014 · Sung-Nan Pei, Ming-Chun Ma, et al. · International Journal of Medical Sciences · 40
PDF
A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy
2016 · Meng-Che Hsieh, Shih-Hor Wang, et al. · Medicine · 36
Satisfaction with pain management and impact of pain on quality of life in cancer patients
2018 · Johnson Lin, Ruey‐Kuen Hsieh, et al. · Asia-Pacific Journal of Clinical Oncology · 34
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis
2017 · Yuan-Hung Kuo, I-Pei Wu, et al. · Investigational New Drugs · 34
Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1–3 axillary lymph node(s) metastasis
2013 · Yu-Li Su, Shan-Hsuan Li, et al. · Radiology and Oncology · 34
PDF
Taiwan nutritional consensus on the nutrition management for gastric cancer patients receiving gastrectomy
2019 · Ping-I. Hsu, Seng-Kee Chuah, et al. · Journal of the Formosan Medical Association · 33
PDF
Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma
2015 · Sheng-Dean Luo, Yi-Ju Chen, et al. · BioMed Research International · 33
PDF
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
2019 · Max W. Sung, Richard S. Finn, et al. · Journal of Clinical Oncology · 32
Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
2016 · Kun-Ming Rau, Han-Ku Chen, et al. · International Journal of Molecular Sciences · 31
PDF
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer
2023 · Tom Wei-Wu Chen, Ming-Shen Dai, et al. · JAMA Oncology · 29
Works count: 105
Citation count: 5,763
H-index: 26
I10-index: 49
Year
Topic
Type